Carbogen Amcis AG has acquired Creapharm Parenterals, a subsidiary of France-based Creapharm Group. Creapharm Parenterals (formerly MP5) is a CDMO specializing in liquid, semi-solid and injectable aseptic dosage forms. As part of this acquisition, Creapharm Parenterals has changed its name to Carbogen Amcis SAS. Financial terms were not disclosed.
 
Mark Griffiths, chief executive officer of Carbogen Amcis, commented, “This exciting transaction further strengthens Carbogen Amcis’ service offerings, enabling us to provide our customers with a complete and reliable manufacturing solution from process development to the supply of pharmaceutical substances and formulated products.”

The acquisition will extend Carbogen Amcis’ range of development and manufacturing services by adding formulation, lyophilization services and sterile GMP capabilities for the fast supply of drug products, including highly potent drugs, for preclinical studies and clinical trials. Creapharm Parenterals has more than 10 years of expertise in the supply of Investigational Medicinal Products (IMP), with more than 300 batches and 145 clinical batches produced since 2000. The company employs 16 specialists and operates a GMP manufacturing site in Riom, France.

“We believe that the combined capabilities and services of our two companies present a one-stop solution to pharmaceutical, biotech and virtual pharmaceutical companies looking for a single reliable partner that can provide API and drug product development for preclinical and clinical studies,” commented Maxime Laugier, development and projects director at Creapharm Parenterals.

“This move reflects our determination to continue to position Carbogen Amcis as a leading service provider for early phase development projects and niche scale commercial products within the Dishman Group of companies,” said Jay Vyas, managing director of the Dishman Group, which owns Carbogen Amcis.